To view this email as a web page, click here.

 
FDA Approves Ixekizumab for Ankylosing Spondylitis
Lilly has announced that it received FDA approval for Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis).
Read more
ADVERTISEMENT
Advertisement
 
The Negative Consequences of a Missed Diagnosis
A missed diagnosis can have negative consequences for patients, making it critical for providers to have a better understanding of vasculitis and its related syndromes. In a presentation given at the Rheumatology Nurses Society annual meeting earlier this month, Jeffrey Kaine, M.D., an independent rheumatology consultant based in Cullowhee, N.C., discussed the challenges in diagnosing and treating vasculitis. In this Q&A, Dr. Kaine covers some of the high points from his talk.
Read more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.